Cargando…
Association between post-operative hPG(80) (circulating progastrin) detectable level and worse prognosis in glioblastoma
BACKGROUND: Patients with glioblastomas have a dismal prognosis, and there is no circulating predictive or prognostic biomarker. Circulating progastrin, hPG(80), is a tumor-promoting peptide present in the blood of patients with various cancers that has been shown to have prognostic value. We evalua...
Autores principales: | Doucet, L., Cailleteau, A., Vaugier, L., Gourmelon, C., Bureau, M., Salaud, C., Roualdes, V., Samarut, E., Aumont, M., Zenatri, M., Loussouarn, D., Quillien, V., Bocquet, F., Payen-Gay, L., Joubert, D., Prieur, A., Robert, M., Frenel, J.-S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594012/ https://www.ncbi.nlm.nih.gov/pubmed/37713930 http://dx.doi.org/10.1016/j.esmoop.2023.101626 |
Ejemplares similares
-
Prognostic Value of Plasma hPG(80) (Circulating Progastrin) in Metastatic Renal Cell Carcinoma
por: Kohli, Manish, et al.
Publicado: (2021) -
The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
por: You, Benoit, et al.
Publicado: (2019) -
Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
por: Prieur, Alexandre, et al.
Publicado: (2023) -
Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma
por: Dupuy, Marie, et al.
Publicado: (2022) -
hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
por: Chauhan, Aman, et al.
Publicado: (2022)